Surgical Treatment for Seizures
Every patient with drug-resistant epilepsy should be referred for surgical evaluation immediately after failure of two appropriately chosen antiseizure medications, regardless of age (up to 70 years), seizure type, epilepsy duration, or comorbidities, as surgery is the only treatment proven to improve survival and reverse excess mortality in drug-resistant epilepsy. 1
Definition of Drug-Resistant Epilepsy
Drug-resistant epilepsy (DRE) is defined as failure of adequate trials of two tolerated, appropriately chosen antiseizure medication schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom. 1 Once this threshold is met, further medication trials have minimal likelihood of success (only 4% achieve seizure freedom with third or subsequent medications), making surgical evaluation the priority. 1
When to Refer for Surgical Evaluation
Immediate Referral Required:
- All patients with confirmed DRE up to age 70 1
- Patients cooperative with management, regardless of:
- Epilepsy duration
- Sex or socioeconomic status
- Seizure type or epilepsy type (including epileptic encephalopathies)
- Localization
- Psychiatric comorbidities (including psychogenic non-epileptic seizures)
- Substance abuse history (if now cooperative)
- Previous failed epilepsy surgery 1
Consider Referral:
- Patients over 70 years without surgical contraindications 1
- Seizure-free patients on 1-2 medications with brain lesion in non-eloquent cortex 1
Do NOT Refer:
- Active substance abuse with non-cooperation with management 1
Critical Timing Considerations
A common and dangerous pitfall is delaying surgical referral. Despite clear evidence, average time from epilepsy onset to surgical evaluation remains approximately 20 years in adults. 1 This delay is associated with:
- Increased morbidity and mortality
- Irreversible cognitive and developmental impairment (especially in children) 2
- Worse surgical outcomes
- Reduced quality of life
Do not delay referral for:
- Trying additional non-medication therapies
- Cases where surgery is expected to be "palliative" only
- Previous surgical failure with ongoing DRE
- Medication failure due to side effects rather than lack of efficacy
- Patient reluctance (if willing to be evaluated/counseled) 1
Surgical Options and Expected Outcomes
Resective Surgery (Gold Standard)
Mesial Temporal Lobe Epilepsy (most common DRE):
- Anterior temporal lobectomy (ATL): 60-80% seizure freedom at 2 years 3, 4
- Selective amygdalohippocampectomy (SAH): 70% seizure freedom 4
- Class I evidence demonstrates superiority over continued medical therapy 5
Extratemporal Lobe Epilepsy:
- 30-60% seizure freedom at 2 years 3
- Lower success rates but still superior to continued medical management
Minimally Invasive Options
Laser Interstitial Thermal Therapy (MRgLITT):
- Seizure freedom rates: 44-78% at 1 year for mesial temporal epilepsy 3
- Multicenter data: 58% seizure freedom, 77% with significant clinical benefit 3
- Advantages: Shorter hospital stay, less surgical morbidity, faster recovery, minimal damage to overlying cortex 3
- Best for: Mesial temporal epilepsy, hypothalamic hamartomas, focal cortical dysplasia, periventricular nodular heterotopia 3
Other minimally invasive approaches:
Neuromodulation (When Resection Not Feasible)
Options include responsive neurostimulation, deep brain stimulation, and vagus nerve stimulation. These reduce seizure frequency but are less likely to achieve seizure freedom compared to resective surgery. 5 Consider when:
- Epileptogenic zone cannot be identified
- Resection would affect eloquent cortex
- Patient preference for non-resective approach
Disconnective Procedures
Hemispherectomy and corpus callosotomy for specific indications (hemimegaloencephaly, catastrophic epilepsies). 6
Contraindications to Surgery
Absolute:
- Inability to identify epileptogenic focus or critical pathways 3
- Inability to undergo MRI (for MRgLITT specifically) 3
- Unstable cardiac/respiratory conditions
- Uncontrollable bleeding diathesis
- Active substance abuse with non-cooperation 3
Critical Outcome Data
Mortality benefit: Surgical treatment normalizes overall mortality even without complete seizure freedom, as long as there is reduction of seizures with impaired awareness. 3 This is the most compelling reason for early referral—surgery is the only treatment proven to reverse excess mortality in DRE. 1
Quality of life: Improved even with seizure reduction (not just freedom) 1
Cost-effectiveness: Surgical evaluation is cost-effective even when likelihood of subsequent resection is less than 5%. 1
Presurgical Workup Components
Evaluation typically includes:
- Video-EEG monitoring
- High-resolution MRI (3T preferred)
- Neuropsychological testing
- Functional imaging (PET, SPECT, fMRI as needed)
- Invasive monitoring (subdural electrodes, stereoelectroencephalography) when non-invasive localization insufficient 6
The key message: Refer early, refer broadly. The surgical team will determine candidacy—your role is timely identification and referral of all patients meeting DRE criteria. 1